» Articles » PMID: 19724902

Involvement of RQCD1 Overexpression, a Novel Cancer-testis Antigen, in the Akt Pathway in Breast Cancer Cells

Overview
Journal Int J Oncol
Specialty Oncology
Date 2009 Sep 3
PMID 19724902
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

We here report identification and characterization of required for cell differentiation 1 homolog (RQCD1) as a potential therapeutic target for breast cancer. Gene-expression profiling analysis of breast cancer cells, semi-quantitative RT-PCR, Northern blotting and Western blotting confirmed RQCD1 to be frequently up-regulated in breast cancer specimens and breast cancer cell lines. On the other hand, its expression was very weak or hardly detectable in normal human tissues except testis, indicating this molecule to be a novel cancer-testis antigen. Treatment of breast cancer cell lines with siRNA targeting RQCD1 drastically suppressed cell proliferation. Concordantly, introduction of exogenous RQCD1 into HEK293 cells significantly enhanced cell growth, implying RQCD1 to have an oncogenic activity. Co-immunoprecipitation experiments and immunocytochemical staining revealed an interaction of RQCD1 protein with Grb10 interacting GYF protein 1 (GIGYF1) and 2 (GIGYF2) proteins, involved in regulation of Akt activation, in breast cancer cells. Interestingly, knockdown of either of RQCD1, GIGYF1 or GIGYF2 resulted in significant reduction of the phosphorylation of Akt at Ser 473 in breast cancer cell lines. Our findings suggest that RQCD1 is a potential molecular target for treatment of breast cancer.

Citing Articles

MicroRNAs from edible plants reach the human gastrointestinal tract and may act as potential regulators of gene expression.

Diez-Sainz E, Milagro F, Aranaz P, Riezu-Boj J, Lorente-Cebrian S J Physiol Biochem. 2024; 80(3):655-670.

PMID: 38662188 PMC: 11502557. DOI: 10.1007/s13105-024-01023-0.


Structure and function of molecular machines involved in deadenylation-dependent 5'-3' mRNA degradation.

Zhao Q, Pavanello L, Bartlam M, Winkler G Front Genet. 2023; 14:1233842.

PMID: 37876592 PMC: 10590902. DOI: 10.3389/fgene.2023.1233842.


The SARS-CoV-2 protein NSP2 impairs the silencing capacity of the human 4EHP-GIGYF2 complex.

Zou L, Moch C, Graille M, Chapat C iScience. 2022; 25(7):104646.

PMID: 35756894 PMC: 9213009. DOI: 10.1016/j.isci.2022.104646.


Functional genomics for breast cancer drug target discovery.

Yoshimaru T, Nakamura Y, Katagiri T J Hum Genet. 2021; 66(9):927-935.

PMID: 34285339 PMC: 8384626. DOI: 10.1038/s10038-021-00962-6.


Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications.

Vanni I, Tanda E, Dalmasso B, Pastorino L, Andreotti V, Bruno W Front Mol Biosci. 2020; 7:172.

PMID: 32850962 PMC: 7396525. DOI: 10.3389/fmolb.2020.00172.